55. Eur J Cancer. 2018 Jun;96:82-90. doi: 10.1016/j.ejca.2018.03.020. Epub 2018 Apr18.Influence of side-effects on early therapy persistence with letrozole inpost-menopausal patients with early breast cancer: Results of the prospectiveEvAluate-TM study.Nabieva N(1), Fehm T(2), Häberle L(3), de Waal J(4), Rezai M(5), Baier B(4),Baake G(6), Kolberg HC(7), Guggenberger M(8), Warm M(9), Harbeck N(10),Wuerstlein R(10), Deuker JU(11), Dall P(12), Richter B(13), Wachsmann G(14),Brucker C(15), Siebers JW(16), Popovic M(17), Kuhn T(18), Wolf C(19), VollertHW(20), Breitbach GP(21), Janni W(22), Landthaler R(23), Kohls A(24), RezekD(25), Noesselt T(26), Fischer G(27), Henschen S(28), Praetz T(29), Heyl V(30),Kühn T(31), Krauss T(32), Thomssen C(33), Hohn A(34), Tesch H(35), MundhenkeC(36), Hein A(1), Hack CC(1), Schmidt K(37), Belleville E(38), Brucker SY(39),Kümmel S(40), Beckmann MW(1), Wallwiener D(39), Hadji P(41), Fasching PA(42).Author information: (1)Department of Obstetrics and Gynecology, Erlangen University Hospital,Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg,Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.(2)Department of Gynecology, Heinrich Heine University of Düsseldorf, Düsseldorf,Germany; Department of Gynecology, University of Tübingen, Tübingen, Germany.(3)Department of Obstetrics and Gynecology, Erlangen University Hospital,Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg,Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany;Biostatistics Unit, Department of Gynecology, Erlangen University Hospital,Erlangen, Germany.(4)Department of Gynecology, Dachau Clinic, Dachau, Germany.(5)Luisen-Hospital Düsseldorf, Düsseldorf, Germany.(6)Oncological Medical Practice Pinneberg, Pinneberg, Germany.(7)Marien-Hospital Bottrop, Bottrop, Germany.(8)Tuttlingen Clinic, Tuttlingen, Germany.(9)Breast Center, Department of Gynecology, Cologne University Hospital, Cologne,Germany; Breast Center, Clinics of Cologne GmbH, Holweide, Cologne, Germany.(10)Breast Center, Department of Gynecology, Cologne University Hospital,Cologne, Germany; University Hospital Munich (LMU), Dept. of Gynecology andObstetrics, Breast Center and CCC Munich, Munich, Germany.(11)Vinzenz-Hospital Hannover GmbH, Hannover, Germany.(12)Department of Gynecology, Lüneburg Clinic, Lüneburg, Germany.(13)Elbland Clinics, Meissen-Radebeul, Germany.(14)County Hospital of Böblingen, Böblingen, Germany.(15)Department of Gynecology, University Hospital, Paracelsus Private MedicalUniversity of Nuremberg, Nuremberg, Germany.(16)Department of Gynecology, St. Josef's Hospital, Offenburg, Germany.(17)Department of Gynecology, Bayreuth Clinic GmbH, CCC ER-EMN, Bayreuth,Germany.(18)Karl-Olga-Hospital Stuttgart, Diakonie Klinikum Stuttgart, Stuttgart,Germany.(19)Medical Center Ulm, Ulm, Germany.(20)Friedrichshafen Clinic, Friedrichshafen, Germany.(21)Department of Gynecology, Neunkirchen Clinic, Neunkirchen, Germany.(22)Department of Gynecology, Ulm University Hospital, Ulm, Germany.(23)Gynecological Medical Practice of the County Hospital of Krumbach, Krumbach, Germany.(24)Evangelic County Hospital Ludwigsfelde-Teltow, Ludwigsfelde-Teltow, Germany.(25)Marien-Hospital Wesel, Wesel, Germany.(26)Department of Gynecology of the County Hospital of Hameln, Hameln, Germany.(27)Mittweida Hospital gGmbH, Mittweida, Germany.(28)Johanniter Hospital Genthin Stendal gGmbH, Hansestadt Stendal, Germany.(29)Caritas-Hospital Bad Mergentheim, Bad Mergentheim, Germany.(30)Asklepios Paulinen Clinic Wiesbaden, Wiesbaden, Germany.(31)Department of Gynecology, Esslingen Clinics a.N., Esslingen, Germany.(32)Department of Gynecology Passau, Passau, Germany.(33)Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle(Saale), Germany.(34)County Hospital Kiel GmbH, Kiel, Germany.(35)Oncology Bethanien Frankfurt, Frankfurt, Germany.(36)Department of Gynecology, University Hospital of Schleswig-Holstein, CampusKiel, Kiel, Germany.(37)Novartis Pharma GmbH Nuremberg, Nuremberg, Germany.(38)Clin-Sol GmbH Würzburg, Würzburg, Germany.(39)Department of Gynecology, University of Tübingen, Tübingen, Germany.(40)Breast Unit, Essen Mitte Clinics, Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.(41)Department of Bone Oncology, Nordwest Hospital, Frankfurt, Germany.(42)Department of Obstetrics and Gynecology, Erlangen University Hospital,Comprehensive Cancer Center Erlangen-European Metropolitan Area Nuremberg,Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany. Electronic address: peter.fasching@uk-erlangen.de.BACKGROUND: Endocrine treatment (ET) with an aromatase inhibitor (AI) is thetreatment of choice in post-menopausal patients with hormone receptor-positiveearly breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuation. This analysis aimed to identify side-effects that lead topatients failing to persist with letrozole treatment.PATIENTS AND METHODS: Post-menopausal hormone receptor-positive EBC patientsstarting ET with letrozole were enroled in EvAluate-TM, a non-interventionalstudy. Information regarding treatment compliance and persistence was gathered inmonths 6 and 12. Persistence was defined as the time from 30 d after the start tothe end of treatment. The influence on persistence of musculoskeletal syndrome,menopausal disorder, sleep disorder and other AEs within the first 30 d wasanalysed using Cox regression analyses.RESULTS: Among 3887 patients analysed, the persistence rate after 12 months was>85%. In all, 568 patients (14.6%) discontinued the treatment, 358 of whom(63.0%) did so only because of side-effects. The main AEs influencing persistencewere musculoskeletal symptoms (hazard ratio [HR] 2.55; 95% confidence interval[CI], 1.90-3.42), sleep disorders (HR 1.95; 95% CI, 1.41-2.70) and other AEs (HR 2.03; 95% CI, 1.51-2.73). Menopausal disorder was not associated withnon-persistence (HR 1.17; 95% CI, 0.74-1.84).CONCLUSIONS: These results suggest that side-effects of AIs such asmusculoskeletal syndrome and sleep disorder lead to ET discontinuation within thefirst treatment year in significant numbers of EBC patients. Complianceprogrammes adapted for subgroups that are at risk for early non-persistence mighthelp to ensure the recommended therapy duration.CLINICAL TRIALS NUMBER: CFEM345DDE19.Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.ejca.2018.03.020 PMID: 29679775 